Form 4: Alkermes COO Granted Stock Options, RSUs

Alkermes plc's EVP and Chief Operating Officer, Blair Curtis Jackson, was granted 94,900 employee stock options and 44,078 restricted stock units.

Summary

• Blair Curtis Jackson, Executive Vice President and Chief Operating Officer of Alkermes plc, received new equity awards.
• The awards include 94,900 employee stock options with an exercise price of $30.25 per share.
• Additionally, 44,078 restricted stock units (RSUs) were granted.
• Both the stock options and restricted stock units will vest in four equal annual installments, commencing on March 2, 2027.
• The transactions for these grants occurred on March 2, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices that align management incentives with shareholder interests, without indicating any immediate operational or financial changes.

Positives

• The grant of equity awards to a key executive like the COO aligns management's long-term interests with those of shareholders.
• A significant number of options and RSUs were granted, indicating continued commitment to executive incentives.

Future Outlook

The filing indicates a future vesting schedule for the equity awards, which is designed to incentivize the executive's long-term performance and retention with the company.

Industry Context

StockSavvy.ai notes that equity grants to senior executives like a Chief Operating Officer are a standard component of compensation packages in the pharmaceutical and biotechnology industry. These grants are typically structured to align executive incentives with long-term company performance and shareholder value creation, fostering retention of key talent.

Comparison to Industry Standards

• The grant of stock options and restricted stock units is a common compensation structure for executives in the biotech sector, comparable to practices at companies like Biogen or Vertex Pharmaceuticals, which frequently use such awards to attract and retain top talent.
• The vesting schedule of four equal annual installments is a standard approach to ensure long-term commitment and performance alignment, similar to what is observed across many S&P 500 companies.

Stakeholder Impact

• Shareholders: Potential positive impact through increased alignment of executive incentives with long-term company performance and value creation.
• Employees: No direct impact on general employees is mentioned in this filing.

Next Steps

• Vesting of the granted stock options and restricted stock units will commence on March 2, 2027, in four equal annual installments.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a key executive, which is a standard compensation practice. It does not provide new information that would fundamentally alter the investment thesis for Alkermes plc, thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Alkermes plc, ALKS, Blair Curtis Jackson, Stock Options, Restricted Stock Units, Equity Grant, Executive Compensation, Insider Transaction, Form 4